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Background and Objectives: Autosomal dominant polycystic kidney disease is a pathology mainly characterized by the 
progressive development and enlargement of cysts in each kidneys. Such as many adult epithelial tissue, renal tubule 
replaces damaged or death cells through the presence of stem/progenitor cells CD133+CD24+ Obviously, in ADPKD 
the repair of damages is insufficient to block the disease, but renal stem cells could have a role in the pathology. 
In this study we investigate the localization and the involvement of cells CD133+CD24+ in ADPKD progression.
Methods and Results: Two normal kidneys and two ADPKD kidneys were examined. CD133 and CD24 expression 
was investigated by confocal microscopy and immunoblotting. Renal tissue and cells were analyzed. CD133 and CD24 
have the same localization in ADPKD tissues and in normal kidneys: a subset of epithelial cells (PEC) of Bowman’s 
capsule and luminal side of tubules. It is interesting that CD133+CD24+ cells are statistically more represented in 
ADPKD tubules (p＜0.001) and in healthy glomeruli (p=0.0016). Cysts express CD133 and CD24.
Conclusions: Renal epithelial progenitors demonstrate to be involved in ADPKD pathogenesis but their role will have 
to be clarified and possibly managed to obtain improvement, or at least stabilization, of disease.
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Introduction
  Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
is a disease which can arise from mutations in either pkd1 
(85%) or pkd2 (15%) with clinically indistinguishable 
manifestation (1). ADPKD affects over 1：1,000 of the 
world wide population and it causes 1：3,000 hospitalization. 
ADPKD is asymptomatic in about 50% of subjects with pkd 
genes mutated (2). It is a systemic disease associated with 
renal failure, intracranial arterial aneurysms, cardiac valv-
ular defects, colonic diverticulosis and cyst formation in 
other organs such as liver, spleen and pancreas. Neverthe-
less ADPKD gives mainly renal manifestations: patients 
develop renal cysts which progressively lead to disruption 
of renal parenchyma, interstitial fibrosis, cellular infiltra-
tion and loss of functional nephrons. Renal degeneration 
finally progresses to end-stage kidney disease. APDKD ac-
counts for up to 10% of all patients on renal replacement 
therapy (1). 
  Pkd-1 (chromosome 16) codes for a big transmembrane 
protein of 460 KDa involved in calcium permeation and 
in cell-cell/matrix interaction. Pkd-2 (chromosome 4) co-
des for a calcium channel of about 110 KDa. The poly-
cystins form together a functional complex. In pathology, 
the alteration of this complex reduces Ca++ flow with ab-
sorption of water in tubules and cysts development (3, 4). 
  Previous studies have demonstrated a high rate of pro-
liferation and apoptosis in the cysts of ADPKD patients 
(4). This unproductive attempt of tissue reparation sug-
gests a likely involvement of renal progenitors.
  During last years, many studies demonstrate the ex-
istence of a renopoietic system. Sagrinati et al. identified, 
in human adult kidneys, a subset of Parietal Epithelial 
Cells (PECs) in the Bowman’s capsule. PECs exhibit 
co-expression of stem cell markers CD24 and CD133 and 
absence of lineage-specific markers. 
  CD133 is a pentaspan transmembrane glycoprotein of-
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ten expressed on adult stem cells, where it is thought to 
function in maintaining stem cell properties by suppress-
ing differentiation and promoting proliferation. CD133 
expression is also associated to several types of cancer 
(5-7). CD133 function is not clear but its presence on early 
and undifferentiated cells is suggestive of a growth factor 
receptor, and the presence of five tyrosine residues on the 
50-aa cytoplasmic tail may indicate that the protein is 
phosphorylated in response to ligand binding and triggers 
a signal transduction (8).
  CD24 is a sialoglycoprotein expressed on mature gran-
ulocytes (9), B and T lymphocyte subsets (10, 11), normal 
and cancer stem cells (12, 13). The protein is anchored 
via a glycosyl phosphatidylinositol to cell surface. It acts 
as adhesion molecule and is involved in cell migration and 
signal transduction.
  CD24+ CD133+ PEC population, which could be puri-
fied from cultured capsulated glomeruli, revealed self-re-
newal potential and high cloning efficiency. Under appro-
priate culture conditions, individual clones of CD24+ 
CD133+ PEC could be induced to generate mature, func-
tional, tubular cells with phenotypic features of proximal 
and/or distal tubules, osteogenic cells, adipocytes, and 
cells that exhibited phenotypic and functional features of 
neuronal cells (14).
  A hierarchical distribution of renal progenitor cells was 
identified in adult human glomeruli. CD24+ CD133+ 
PECs are localized in the urinary pole and are in close 
contiguity with podocytes to the vascular stalk and with 
tubular renal cells to the other extremity. A transitional 
cell population displays features of either renal progeni-
tors or podocytes and localizes between urinary pole and 
vascular pole. In the vascular stalk of the glomerulus, 
transitional cells are localized in close continuity with 
cells without progenitor markers but positive to podocyte 
markers. They will become committed podocytes. In the 
urinary pole, CD24+ CD133+ PECs will progressively be-
come proximal tubular cells (15).
  When CD24+ CD133+ PECs were isolated and injected 
into SCID mice with acute renal failure from glycerol-in-
duced rhabdomyolysis, they induced regeneration of dif-
ferent portions of the nephron, reduced tissue necrosis and 
fibrosis and significantly improved renal function. No tu-
morigenic potential was observed (16). In a recent study, 
it was hypothesized that PECs were able to delay fibrotic 
response and inflammation process in chronic injury caus-
es dysfunction of the tubular epithelial cells. This effect 
could allow to tissue regeneration rather than scar for-
mation (17). Regenerative response in post-transplant 
acute tubular necrosis, underlying Delayed Graft Function 
(DGF), was characterized by an increase of proliferating 
PECs involved in repairing tubular damage (18).
  ADPKD is characterized by expansion of cysts and tub-
ular hyperplasia. So it is probable that PECs are involved 
in the pathophysiology of ADPKD through an attempt of 
unsuccessful tissue repair.
Materials and Methods
Antibodies
  CD133 monoclonal (293C3) antibody for immuno-
fluorescence was provided by Miltenyi Biotec (Miltenyi 
Biotec, Bergisch Gladbach, Germany). CD133 monoclonal 
(W6B9C1) antibody for Western blot was provided by 
Miltenyi Biotec (Miltenyi Biotec, Bergisch Gladbach, 
Germany). CD24 monoclonal (SN3) antibody was provided 
by Santa Cruz (Santa Cruz Biotechnology Inc., Santa Cruz 
CA, USA). PKD1 rabbit polyclonal (H-260) antibody was 
provided by Santa Cruz (Santa Cruz Biotechnology Inc., 
Santa Cruz CA, USA). Goat anti mouse IgG2b-Alexa 568 
conjugate, goat anti mouse IgG2b-Alexa 633 conjugate, 
goat anti mouse IgG1-Alexa 568 conjugate, goat anti rabbit 
IgG-Rhod conjugate, goat anti mouse IgG-HRP conjugate 
were used as secondary antibodies.
Tissues
  Normal kidney fragments was obtained from a cadaveric 
kidney donor. The kidney was not suitable for transplantation 
due to the incidental discovery of a neoplastic nodule of 5 
cm at the lower pole upon macroscopic examination. The 
pathologic examination diagnosed a clear cell carcinoma 
(grade 2 according to Fuhrman classification; T1bN0M0 ac-
cording to the International Union Against Cancer classi-
fication); the lower pole was excised and the remaining paren-
chyma was used in the following procedures. The remaining 
parenchyma did not reveal any evidence of clear cell 
carcinoma.
  Polycystic kidney tissue was obtained from 2 ADPKD 
patients underwent to nephrectomy in preparation for re-
ceiving renal transplantation. All procedures were pre-
ceded by the approval of our Local Ethical Committee on 
human experimentation and informed consent was ob-
tained from the patients.
Colture
  Human Kidney 2 cells (HK-2) were maintained in 
DMEM F-12 (Invitrogen/GIBCO, Cralsbad, California) 
supplementated with 10% FBS (PAA laboratories GmbH, 
Pasching, Austria), 2,000 U/ml penicillin (PAA laboratories 
GmbH, Pasching, Austria), 2,000 ug/ml streptomycin (PAA 
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laboratories GmbH, Pasching, Austria), and 20 mM L-glu-
tamine (Invitrogen/GIBCO, Cralsbad, California).
  Human Embryonic Kidney 293 cells (HEK-293) were man-
teined in DMEM (Invitrogen/GIBCO, Cralsbad, California) 
supplementated with 5% FBS (PAA laboratories GmbH, 
Pasching, Austria), 2,000 U/ml penicillin (PAA laboratories 
GmbH, Pasching, Austria), 2,000 ug/ml streptomycin (PAA 
laboratories GmbH, Pasching, Austria), and 20 mM L-gluta-
mine (Invitrogen/GIBCO, Cralsbad, California).
  HK-2 and HEK-293 were grown two weeks and medium was 
changed every two days. After every week, cells were washed 
with PBS (PAA laboratories GmbH, Pasching, Austria) and 
were trypsinizated (Invitrogen/GIBCO, Cralsbad, California). 
Cells harvested were, in part, seeded on chambers slides and 
the others were used to extract proteins.
  Cystic cells were obtained by fragments of renal cysts 
deprived of external membrane. Each cysts was picked up, 
was divided in some little fragments and were digested by 
collagenase (Invitrogen/GIBCO, Cralsbad, California) for 
one hours. Every pieces of a single cysts were seeded on 
a plate, previously treated by collagene type I (Invitrogen/ 
GIBCO, Cralsbad, California), the same medium used for 
HK-2. 
Immunofluorescence
  Three-micrometer frozen kidney samples mounted on 
Super Frost Plus slides (Menzel-Gläser, Thermo Scientific, 
Waltham, MA) were cut by a cryostat (Leica 1720, Leica 
Mycrosystems, Heerbrog, Germany). The sections, or cel-
lular spots, were fixed with PFA for 10 min, washed with 
PBS. Slides were coated (3% Bovine Serum Albumin in 
PBS buffer) for 1 h at 20oC. Slides were incubated by pri-
mary antibody for 1 h at 37oC, washed with PBS and suc-
cessively incubated by secondary antibody for 1 h at 20oC. 
Primary and secondary antibodies were diluted in coating 
solution. Slides were closed with Vectashield® Mounting 
Medium with DAPI (Vector Laboratories, Inc., Burlingame, 
CA, USA). Tissue samples, or cells, were examined by im-
munofluorescence microscopy (Olympus BX41 Microscopy). 
Confocal images were obtained with Leica TCS SP2 
(Leica Microsystems, Heerbrog, Germany).
Image analysis
  Images of immunofluorescence-marked kidney were 
sampled by an acquisition system composed by Olympus 
BX41 microscope, Olympus XC30 and CELL B 3.0 analy-
sis image processing (Olympus Europa GmbH, Hamburg 
Germany). Images were saved in tagged image file format 
(.tiff), a file type better handled by graphic software. The 
files were analyzed with Inspector Matrox (Matrox Electronic 
System Ltd., Quebec Canada), a professional graphic 
software. ROI defines a portion of image that contains 
areas to analyze. ROIs of each renal component (tubules, 
glomeruli and cysts) were sampled. The ROIs were con-
verted in a list of single grey tone amount, from white 
(highest value) to black (zero). Background fluorescence 
was obtained sampling spot of negative structure, such 
mesangium or negative tubules, in every image. 
Statistical analysis
  Total brightness/positive area ratio was calculated for 
each ROI. The following analysis of expression were per-
formed: CD24+ in tubules of normal tissue, CD24+ in glo-
meruli of normal tissue, CD24+ in tubules of ADPKD 
samples, CD24+ in glomeruli of ADPKD samples, CD24+ 
in cysts of ADPKD samples, CD133+ in tubules of normal 
samples, CD133+ in glomeruli of normal tissue, CD133+ 
in tubules of ADPKD samples, CD133+ in glomeruli of 
ADPKD samples, CD133+ in cysts of ADPKD samples. 
Normal and ADPKD tissue components were compare by 
Mann-Whitney test. Results were considered statistically 
significant for p＜0.01.
Western blot analysis
  Total proteins were extracted from cellular pellets with 
Triton X-100 based lysis buffer. Proteins were loaded on 
SDS-PAGE (3% stacking, 7,5% resolving), previously de-
natured with 4X Reducing Loading Buffer (200 mM 
TrisHCl, 20% β-Mercapto Ethanol, 8% SDS, 0.4% 
Bromofenol Blue, 40% glycerol). After SDS-PAGE run 
and transblot, nitrocellulose membranes were previously 
incubated by antibodies anti-CD133 and anti-CD24 and 
subsequently by horse radish peroxidise conjugated secon-
dary antibodies. The detection was obtained by exposition 
of radiological plates to peroxidise substrate activated by 
the enzyme.
Results
Expression of CD133 and CD24 in normal kidney
  Confocal microscopy analysis shows that CD133 and 
CD24 are expressed by a subset of PECs of Bowman’s cap-
sule in normal kidney glomeruli (Fig. 1: on line pub-
lication). Moreover, tubular distribution of CD133 and 
CD24 is focal and segmental. Interestingly, CD133 is po-
larized to the luminary side of the tubular cells and pos-
itive PECs, whereas CD24 is not clearly polarized showing 
a diffuse distribution (membrane and cytoplasm) (Fig. 1: 
on line publication).
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Fig. 1. (On line publication). CD133 and CD24 expression in nor-
mal kidney. The first lane shows tissue expression of CD133 in
Bowman's capsules and tubules. CD133 is expressed in a subset 
of PEC in the Bowman's capsule and in the luminal side of positive
tubule cells. The second lane shows tissue expression of CD24 in
Bowman's capsules and tubules. CD24 is expressed in a subset of
PEC in the Bowman's capsule and in the cytoplasm of tubule cells.
Expression of CD133+ and CD24+ in ADPKD kidney
  Confocal microscopy analysis of ADPKD kidneys re-
vealed that CD133 and CD24 were expressed by the same 
subset of glomerular (Fig. 2A∼C) and tubular (Fig. 2D∼
F) cells and they showed the same tissue and cellular lo-
calization (Fig. 3: on line publication) of normal kidney: 
PECs in Bowman’s capsule and focal and segmental ex-
pression in tubules. Nevertheless, the quantitative compar-
ison between normal kidney and ADPKD kidney revealed 
an increased CD133 expression in tubules and a reduced 
CD133 expression in glomeruli of ADPKD samples (Fig. 
4). After image analysis Mann-Whitney test resulted stat-
istically significant for these comparisons (ADPKD tubules 
vs Normal tubules: z=−7.681 p＜0.001; ADPKD 
Glomerula vs Normal Glomerula: z= 3.162 p=0.0016). 
CD 24 expression in glomeruli and tubules does not show 
quantitative difference between normal and ADPKD sam-
ples (Fig. 5: on line publication).
  The cysts of ADPKD samples were diffusely positive for 
CD133 and CD24. The cells of large cysts show a flatted 
morphology with co-localization of CD133 and CD24 (Fig. 
2G∼I).
Expression of CD133 and CD24 in cultured cells
  Cystic cultured cells showed a characteristic expression 
pattern for CD133 and CD24 (Fig. 3C: on line pub-
lication): CD133 localized on cellular membrane (Fig. 3A: 
on line publication) whereas CD24 was globally diffused 
into cytoplasm (Fig. 3B: on line publication). The same 
pattern was appreciable in HK-2 cells; on the other hand, 
both antigens presented a cytoplasmic distribution in 
HEK-293 (Fig. 6: on line publication). Western blot analy-
sis revealed that CD133 is highly expressed in cystic cells, 
while HK-2 and HEK-293 showed a reduced level of the 
protein (Fig. 7, higher bands). Analogous amounts of CD24 
were detected in the three cellular populations (Fig. 7, 
lower bands).
Discussion
  The presence of PECs in ADPKD kidney suggests that 
the pathologic tissue tries to repair damages with cellular 
hyperproliferation. This is a common reaction of many tis-
sue to the injuries. The results show unchanged high-amount 
of CD24 in ADPKD tubules and ADPKD glomeruli com-
pared by the healthy component, but increased amounts 
of CD133 in ADPKD tubules and decreased amount of 
CD133 in ADPKD glomeruli. These evidences suggest a 
gradual depletion of CD133+ CD24+ progenitors from glo-
meruli and their accumulation in tubules, the tissue com-
ponent which is directly involved in ADPKD. It also inter-
esting to note the double positivity to CD133 and CD24 
of the cysts. We think that the cysts derived from damaged 
ADPKD tubules wherein chemoactracted-CD133+CD24+ 
progenitors try to repair the tissue with no success, but 
on the contrary triggering the uncontrolled proliferation 
charactering cyst development. 
  Obviously many aspects contribute to ADPKD development. 
Hyperplasia and cysts growth depend also on the lack of 
inhibition of STAT 6 and mTOR by mutated PC1 (4, 19, 
20). The inability of polycystin complex to recover cal-
cium ions from lumen increased the osmolarity of the flu-
id which flows in the tubules, causing attraction of water 
and the increase of volume.
  In B lymphocytes CD24 is an important co-stimulus of 
cell activation and is involved in Ca++ uptake (21). CD133 
localization on cellular membrane suggests an implication 
in cell signaling, in particular the ability to link specific 
ligand or act like sensor for alteration of liquid contained 
in fold. CD133 is mutated in several pathology charac-
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Fig. 2. CD133 and CD24 expression
in ADPKD samples. The first lane 
shows glomerular expression of 
CD133 (A) and CD24 (B). CD133 
and CD24 are co-localized and 
co-expressed by a subset of PEC in 
the Bowman's capsule (C). The sec-
ond lane shows tubular expression 
of CD133 (D) and CD24 (E). CD133
and CD24 are co-localized and 
co-expressed by the luminal side of 
tubules (F). The third lane shows 
cystic expression of CD133 (G) and 
CD24 (H). CD133 and CD24 are 
co-localized and co-expressed by 
the cystic cells (I). 
Fig. 3. (On line publication). CD133
and CD24 expression in cystic cells.
CD133 is closely expressed by the
cellular membrane (A). CD24 is ex-
pressed in the cytoplasm (B). CD133
and CD24 are co-expressed by the 
cystic cells (C).
70  International Journal of Stem Cells 2012;5:65-72
Fig. 4. Morphometric analysis of CD133 expression in tubules and
glomerula of normal kidney and ADPKD kidney. CD133 ex-
pression is higher in ADPKD tubules than in normal tubules (*p
＜0,001) (A). CD133 expression is higher in normal glomerula than
ADPKD glomerula (†p=0,0016) (B).
Fig. 7. Western blot analysis of CD133 and CD24 expression in
untreated HEK-293, HK-2 and cystic cells. Cystic cells express the
highest amount of CD133 whereas HEK-293 the lowest. CD24 
amount is similar in the three populations. 
Fig. 6. (On line publication). CD133 and CD24 expression in cel-
lular lines. HK-2 show a similar antigen-expression patternto cystic
cells: CD133 is localized on the cellular membrane and CD24 is
localized in the cytoplasm. HEK-293 have a diffused and low cel-
lular expression of CD133 and CD24.
Fig. 5. (On line publication). Morphometric analysis of CD24 ex-
pression in tubules and glomerula of normal kidney and ADPKD 
kidney. CD24 expression is not statistically different in both normal
tubules vs ADPKD tubules (A) and normal glomerula vs ADPKD
glomerula (B) comparison.
terized by retinal degeneration, such as retinitis pigmento-
sa and Stargardt disease (22, 23). The most common forms 
of Stargardt disease are associated with mutation of gene 
coding ATP-binding cassette transporters. It is possible 
that CD133 could be involved in cellular molecule exchanges. 
In a cellular subset where polycystin are not able to main-
tain Ca++ gradient and other systems of Ca++ flow control 
are physiologically switch off, PECs are potentially and 
paradoxically dangerous for kidney.
  ADPKD pathogenesis is an unsolved paradigm. It is not 
clear if ADPKD late onset is due to haploinsufficiency or 
loss of heterozygosity (LOH). Theory of haploinsufficiency 
is supported by the progressive worsening of ADPKD phe-
notype, e.g., major frequency of cerebral aneurism, asso-
ciated with less-conservative mutation of pkd1 gene. Theory 
of LOH is supported by the evidence that not all tubules 
become cysts. We think that cellular hyperproliferation is 
the base of cyst formation. Tubular damage is the event 
which trigs cyst development. Without injuries, ADPKD 
tubules have a normal behavior. However, during renal fil-
tration tubules could be damaged and this event draws 
PECs and activates cell proliferation. Probably, more trun-
cated proteins compromise membrane stability, make cells 
more sensitive to injuries and cyst formation becomes 
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easier. From this point of view PECs assume a crucial role 
in ADPKD pathogenesis.
  Nevertheless, it is also likely that a local block of cell 
proliferation risks to worsen kidney health because of 
damages persistence.
  We conclude that PECs could have a complex role in 
ADPKD pathogenesis and it is important to control their 
hyperproliferation. In order to deepen this issue, we are 
trying to evaluate several antiproliferative drugs used in 
nephrologic practice with the aim to control cell pro-
liferation and stabilize ADPKD.
Abbreviations
  Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  Parietal Epithelial Cell (PEC)
  Delayed graft function (DGF)
  Human Kidney 2 cells (HK-2)
  Human Embryonic Kidney 293 cells (HEK-293)
  Loss Of Heterozygosity (LOH)
Disclosures
  The authors certify that there is no conflict of interest 
with any financial organization regarding the material dis-
cussed in the manuscript.
Acknowledgments
  This study was supported by the Research Program 
“Regione-Università 2007-2009 - Innovative Research” 
granted by the Regional Sanitary Service of Emilia 
Romagna, Italy. Thanks to nephrology department of 
Modena Polyclinic, in particular to Prof. Gianni Cappelli 
and Riccardo Magistroni.
Potential conflict of interest
  The authors have no conflicting financial interest.
References
1. Chang MY, Ong AC. Autosomal dominant polycystic kidney 
disease: recent advances in pathogenesis and treatment. 
Nephron Physiol 2008;108:1-7
2. Wei W, Hackmann K, Xu H, Germino G, Qian F. 
Characterization of cis-autoproteolysis of polycystin-1, the 
product of human polycystic kidney disease 1 gene. J Biol 
Chem 2007;282:21729-21737
3. Delmas P, Padilla F, Osorio N, Coste B, Raoux M, Crest 
M. Polycystins, calcium signaling, and human diseases. 
Biochem Biophys Res Commun 2004;322:1374-1383
4. Weimbs T. Polycystic kidney disease and renal injury re-
pair: common pathways, fluid flow, and the function of pol-
ycystin-1. Am J Physiol Renal Physiol 2007;293:F1423-1432
5. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, 
Fazioli F, Pirozzi G, Papaccio G. Human primary bone sar-
comas contain CD133+ cancer stem cells displaying high tu-
morigenicity in vivo. FASEB J 2011;25:2022-2030
6. Lorico A, Rappa G. Phenotypic heterogeneity of breast can-
cer stem cells. J Oncol 2011;2011:135039
7. Janikova M, Skarda J, Dziechciarkova M, Radova L, 
Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova 
K, Klein J, Grygarkova I, Kolek V. Identification of 
CD133+/nestin+ putative cancer stem cells in non-small cell 
lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc 
Czech Repub 2010;154:321-326
8. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, 
Holden JT, Bray RA, Waller EK, Buck DW. A novel 
five-transmembrane hematopoietic stem cell antigen: iso-
lation, characterization, and molecular cloning. Blood 1997; 
90:5013-5021
9. Kobayashi SD, Voyich JM, Whitney AR, DeLeo FR. 
Spontaneous neutrophil apoptosis and regulation of cell sur-
vival by granulocyte macrophage-colony stimulating factor. 
J Leukoc Biol 2005;78:1408-1418
10. Vlková M, Fronková E, Kanderová V, Janda A, Ruzicková 
S, Litzman J, Sedivá A, Kalina T. Characterization of lym-
phocyte subsets in patients with common variable im-
munodeficiency reveals subsets of naive human B cells 
marked by CD24 expression. J Immunol 2010;185:6431-6438
11. Berga-Bolaños R, Drews-Elger K, Aramburu J, López-Rodríguez 
C. NFAT5 regulates T lymphocyte homeostasis and CD24-de-
pendent T cell expansion under pathologic hypernatremia. J 
Immunol 2010;185:6624-6635
12. Jiang W, Sui X, Zhang D, Liu M, Ding M, Shi Y, Deng 
H. CD24: a novel surface marker for PDX1-positive pancre-
atic progenitors derived from human embryonic stem cells. 
Stem Cells 2011;29:609-617
13. Myung JH, Gajjar KA, Pearson RM, Launiere CA, 
Eddington DT, Hong S. Direct measurements on CD24- 
mediated rolling of human breast cancer MCF-7 cells on 
E-selectin. Anal Chem 2011;83:1078-1083
14. Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, 
Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini 
M, Gesualdo L, Francini F, Maggi E, Annunziato F, 
Lasagni L, Serio M, Romagnani S, Romagnani P. Isolation 
and characterization of multipotent progenitor cells from 
the Bowman's capsule of adult human kidneys. J Am Soc 
Nephrol 2006;17:2443-2456
15. Romagnani P. Toward the identification of a “renopoietic 
system”? Stem Cells 2009;27:2247-2253
16. Lazzeri E, Crescioli C, Ronconi E, Mazzinghi B, Sagrinati 
C, Netti GS, Angelotti ML, Parente E, Ballerini L, Cosmi 
L, Maggi L, Gesualdo L, Rotondi M, Annunziato F, Maggi 
E, Lasagni L, Serio M, Romagnani S, Vannelli GB, 
Romagnani P. Regenerative potential of embryonic renal 
multipotent progenitors in acute renal failure. J Am Soc 
Nephrol 2007;18:3128-3138
17. Romagnani P, Kalluri R. Possible mechanisms of kidney 
repair. Fibrogenesis Tissue Repair 2009;2:3
72  International Journal of Stem Cells 2012;5:65-72
18. Loverre A, Capobianco C, Ditonno P, Battaglia M, 
Grandaliano G, Schena FP. Increase of proliferating renal 
progenitor cells in acute tubular necrosis underlying de-
layed graft function. Transplantation 2008;85:1112-1119
19. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, 
Kinter MT, Kane ME, Obara T, Weimbs T. Polycystin-1, 
STAT6, and P100 function in a pathway that transduces cil-
iary mechanosensation and is activated in polycystic kidney 
disease. Dev Cell 2006;10:57-69
20. Weimbs T. Regulation of mTOR by polycystin-1: is poly-
cystic kidney disease a case of futile repair? Cell Cycle 
2006;5:2425-2429
21. Fischer GF, Majdic O, Gadd S, Knapp W. Signal trans-
duction in lymphocytic and myeloid cells via CD24, a new 
member of phosphoinositol-anchored membrane molecules. 
J Immunol 1990;144:638-641
22. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler 
JC, Bridges RJ, Kumaramanickavel G, John S, Nancarrow 
D, Röper K, Weigmann A, Huttner WB, Denton MJ. A fra-
meshift mutation in prominin (mouse)-like 1 causes human 
retinal degeneration. Hum Mol Genet 2000;9:27-34
23. Shmelkov SV, St Clair R, Lyden D, Rafii S. AC133/CD133/ 
Prominin-1. Int J Biochem Cell Biol 2005;37:715-719
